Table 4.

Examples of Genetic Strategies Using Secreted AVPs

Secreted AVP	Target	Vector	Promoter	Target Cells	Model System	sAVP Concentration	Outcome
Soluble receptor (sCD4)	gp120	LV	EF1α	CD34	hu-mice	100 ng/mL	control of HIV replication after infection119
	CD4bs
mAb b12-IgA	gp120	LV	MHa	CD34	hu-mice	10 ng/mL	partial protection against infection111
	CD4bs
mAb 2G12	gp120	LV	PGM	CD34	hu-mice	40 ng/mL	partial protection against infection110
	glycans
mAb b12	gp120	AAV2	CMV (HC)	muscle	hu-mice	8 μg/mL	NA123
	CD4bs		EF1α (LC)
mAb VRC07G54W	gp120	AAV8	CASIb	muscle	hu-mice	100 μg/mL	protection against infection124
	CD4bs
mAb 10-1074	gp120	AAVc	thyroglobulin	muscle	hu-mice	200 mg/mL	suppression of HIV replication after infection126
	glycans
Simian scFv-IgG1 (4L6 or 5L7)	gp120	AAV1	CMV	muscle	macaques	1–270 μg/mL	immunogenic; protection against infection dependent on lower immune responses against the secreted AVP127
	NA
Simian mAb (4L6 and 5L7)	gp120	AAV1	CMV	muscle	macaques	1–270 μg/mL	immunogenic; partial protection against infection128
	NA
Siminized mAB VRC07	gp120	AAV8	β-actin	muscle	macaques	66 μg/mL	immunogenic; protection against infection when immune suppressant were used129
	CD4bs
Rhesus sCD4-IgG1	gp120	AAV1	CMV	muscle	macaques	3–10 μg/mL	immunogenic; protection against infection dependent on lower immune responses against the secreted AVP127
	CD4bs
Rhesus eCD4-Ig	gp120	AAV2	CMV	muscle	macaques	17–77 μg/mL	less immunogenic than mAbs; protection against infection130
	CD4bs CORbs

hu-mice, humanized mice.

^aB cell-specific promoter containing Eμ enhancer and MAR upstream of human μ heavy-chain promoter.

^bA combination of the CMV enhancer, the chicken β-actin promoter, and the ubiquitin enhancer region flanked by a splice donor and splice acceptor.

^cSerotype not specified.